Diagnose PET Scan Radiation 
AuntMinnie
MARCH 26, 2024
The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.
Future Teleradiology
NOVEMBER 30, 2023
Teleradiology & Radiology data for artificial intelligence (AI) Introduction: Embark on a journey into the world of medical imaging as we unravel the distinctions between two powerful diagnostic tools—Computed Tomography (CT) scans and Positron Emission Tomography (PET) scans.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Midstate Radiology Associates
SEPTEMBER 19, 2024
Depending on the disease’s progression, your doctor may recommend surgery, chemotherapy, radiation therapy or a combination of these treatments. This procedure is less invasive than other methods and provides a higher level of detail compared to traditional X-rays, while also reducing radiation exposure.
AuntMinnie
JUNE 20, 2024
The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.
Imaging Technology
MAY 31, 2023
We can’t treat what we don’t see, which is why we require precise image quality to help diagnose, plan treatment for, and monitor disease,” explains Prof. Medical imaging is a crucial tool for diagnosing disease, identifying a course of treatment, and determining whether therapy is successful for millions of patients around the world.
Imaging Technology
MAY 2, 2023
milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 18F-rhPSMA-7.3 on behalf of the SPOTLIGHT Study Group.
Imaging Technology
MAY 30, 2023
Results demonstrated high detection rates (% positive PET scans) even at low PSA levels. in Newly Diagnosed Prostate Cancer Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3
Expert insights. Personalized for you.
306 
Let's personalize your content